References
- Patsos HA, Hicks DJ, Greenhough A, Williams AC, Paraskeva C. Cannabinoids and cancer: potential for colorectal cancer therapy. Biochem Soc Trans 2005; 33: 712–4
- Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74: 129–80
- Blazquez C, Gonzalez-Feria L, Alvarez L, Haro A, Casanova ML, Guzman M. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res 2004; 64: 5617–23
- Di Carlo G, Izzo AA. Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Exp Opin Invest Drugs 2003; 12: 39–49
- Bifulco M, Laezza C, Portella G, Vitale M, Orlando P, De Petrocellis L, et al. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J 2001; 15: 2745–7
- Bifulco M, Laezza C, Valenti M, Ligresti A, Portella G, Di Marzo V. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J 2004; 18: 1606–8
- Ligresti A, Bisogno T, Matias I, De Petrocellis L, Cascio MG, Cosenza V, et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 2003; 125: 677–87
- De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M, et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci USA 1998; 95: 8375–80
- Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M, et al. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 2000; 141: 118–26
- Vigna SR. Cannabinoids and the gut. Gastroenterology 2003; 125: 973–5
- Gonzalez S, Mauriello-Romanazzi G, Berrendero F, Ramos JA, Franzoni MF, Fernandez-Ruiz J. Decreased cannabinoid CB1 receptor mRNA levels and immunoreactivity in pituitary hyperplasia induced by prolonged exposure to estrogens. Pituitary 2000; 3: 221–6
- Di Leo A, Messa C, Cavallini A, Linsalata M. Estrogens and colorectal cancer. Curr Drug Targets-Immune. Endocr Metab Disorders 2001; 1: 1–12
- Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999; 106: 574–83
- Al-Azzawi F, Wahab M. Estrogen and colon cancer: current issues. Climateric 2002; 5: 3–14
- Xu X, Thomas ML. Estrogen receptor-mediated direct stimulation of colon cancer cell growth in vitro. Mol Cell Endocrinol 1994; 105: 197–201
- Singh S, Paraskeva C, Gallimore PH, Sheppard MC, Langman MJ. Differential growth response to oestrogen of premalignant and malignant colonic cell lines. Anticancer Res 1994; 14: 1037–42
- Di Domenico M, Castoria G, Bilancio A, Migliaccio A, Auricchio F. Estradiol activation of human colon carcinoma-derived Caco-2 cell growth. Cancer Res 1996; 56: 4516–21
- Messa C, Pricci M, Linsalata M, Russo F, Di Leo A. Inhibitory effect of 17β-estradiol on growth and the polyamine metabolism of a human gastric carcinoma cell line (HGC-27). Scand J Gastroenterol 1999; 34: 79–84
- Messa C, Russo F, Pricci M, Di Leo A. Epidermal growth factor and 17β-estradiol effects on proliferation of a human gastric cancer cell line (AGS). Scand J Gastroenterol 2000; 35: 753–8
- Messa C, Notarnicola M, Russo F, Cavallini A, Pallottini V, Trentalance A, et al. Estrogenic regulation of cholesterol biosynthesis and cell growth in DLD-1 human colon cancer cells. Scand J Gastroenterol 2005; 40: 1454–61
- Lamon-Fava S, Ordovas JM, Schaefer EJ. Estrogen increases apolipoprotein (Apo) A-I secretion in Hep G2 cells by modulating transcription of the Apo A-I gene promoter. Arterioscler Thromb Vasc Biol 1999; 19: 2960–5
- MacCarrone M, De Felici M, Bari M, Klinger F, Siracusa G, Finazzi-Agrò A. Down-regulation of anandamide hydrolase in mouse uterus by sex hormones. Eur J Biochem 2000; 267: 2991–7